Tert-Butylamine

Tert-Butylamine

SCHEMBL4158429

CC(C)(C)N.CC(C)C[C@H](C#N)CC(=O)O

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACEIDH1

The experimentally established mechanism targets of Tert-Butylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 2/20 0.43
CACNB3 P54284 1/20 0.43
CACNA1C Q13936 1/20 0.43
PGR P06401 1/20 0.43
ADRA1A P35348 1/20 0.43
HTR2B P41595 1/20 0.43
CACNA2D2 Q9NY47 1/20 0.43
SLC7A5 Q01650 1/20 0.35
CTSS P25774 2/20 0.34
CTSK P43235 2/20 0.34
CTSL P07711 1/20 0.34
CTSB P07858 1/20 0.34
MME P08473 2/20 0.32
DPP4 P27487 2/20 0.32
SLC1A3 P43003 1/20 0.32
SLC1A2 P43004 1/20 0.32
RNPEP Q9H4A4 1/20 0.31
CPA1 P15085 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tert-Butylamine SCHEMBL4158435 1.00 CACNA2D1 (0.43) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL16576 0.91 CACNA2D1 (0.45) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL2637586 0.91 CACNA2D1 (0.45) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL16694 0.91 CACNA2D1 (0.45) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL262563 0.89 CACNA2D1 (0.44) CACNA2D1CACNB3CACNA1CPGRADRA1A
Ammonia Solution, Strong SCHEMBL3024172 0.89 CACNA2D1 (0.44) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL262562 0.89 CACNA2D1 (0.44) CACNA2D1CACNB3CACNA1CPGRADRA1A
Ammonia Solution, Strong SCHEMBL3024177 0.89 CACNA2D1 (0.44) CACNA2D1CACNB3CACNA1CPGRADRA1A
Tert-Butylamine SCHEMBL4383780 0.82 CACNA2D1 (0.31) CACNA2D1CACNB3CACNA1CPGRADRA1A
SCHEMBL4390679 0.81 CACNA2D1 (0.41) CACNA2D1CACNB3CACNA1CPGRADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090124820-A1 C1-Symmetric Bisphospine Ligands and Their Use in the Asymmetric Synthesis of Pregabalin PFIZER INC. 2009-05-14 US disclosed
EP-1727620-B1 C1-SYMMETRIC BISPHOSPHINE LIGANDS AND THEIR USE IN THE ASYMMETRIC SYNTHESIS OF PREGABALIN WARNER LAMBERT CO (US) 2007-08-29 EP disclosed
EP-1727620-A1 C1-SYMMETRIC BISPHOSPHINE LIGANDS AND THEIR USE IN THE ASYMMETRIC SYNTHESIS OF PREGABALIN Warner-Lambert Company LLC (US) 2006-12-06 EP disclosed
US-20050228190-A1 C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin BAO JIAN 2005-10-13 US disclosed
WO-2005087370-A1 C1-SYMMETRIC BISPHOSPHINE LIGANDS AND THEIR USE IN THE ASYMMETRIC SYNTHESIS OF PREGABALIN WARNER-LAMBERT COMPANY LLC (US) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228190-A1 C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin GABRA5, CNR1, GABRE CACNA2D1 276/4885CACNB3 261/4885CACNA1C 185/4885
US-20090124820-A1 C1-Symmetric Bisphospine Ligands and Their Use in the Asymmetric Synthesis of Pregabalin GABRE, GABRP, GABRA5 CACNA2D1 260/4885CACNB3 244/4885CACNA1C 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.